半定量3T脑磁共振成像动态可视化人脑类淋巴-淋巴流体运输系统:一项先导研究
该先导研究纳入20名神经精神病史无异常的志愿者,在3T MRI上于注射钆对比剂前、注射后即刻及注射后60分钟三个时间点采集序列,发现类淋巴-淋巴流体运输系统在2D T2-FLAIR和3D T1-SPACE序列显示最佳,其信号强度在注射后即刻显著升高、60分钟时显著下降,而脑脊液、灰质和白质信号无显著变化。
要点
- 类淋巴-淋巴流体运输系统在2D T2-FLAIR与3D T1-SPACE序列显示最佳,可用于信号强度测量。
- 3D T1-SPACE序列中该系统信号强度注射后即刻升高86.3±25.2%,60分钟时下降25.4±9%。
- 脑脊液、灰质与白质信号强度在三个时间点间无显著变化。
核心结论
- 建立了可视化类淋巴-淋巴流体运输系统中淋巴管的临床MRI研究方案,并描述了该系统随时间动态变化,可能反映其清除功能。
研究设计与样本
- 先导研究,纳入20名神经精神病史无异常的志愿者,行3T MRI,于对比剂注射前(TP1)、注射后即刻(TP2)和注射后60分钟(TP3)三个预设时间点采集序列,每个序列块依次包含全脑3D T1-MPRAGE、全脑3D T2-FLAIR、聚焦2D T2-FLAIR和全脑3D T1-SPACE,采用广义线性混合模型分析信号强度时间过程,并校正年龄、认知功能(蒙特利尔认知评估量表)和睡眠质量(匹兹堡睡眠质量指数问卷)。
关键影像表现/征象
- 类淋巴-淋巴流体运输系统在2D T2-FLAIR和3D T1-SPACE序列显示最佳,可进一步测量信号强度。
- 对比剂注射前(TP1),该系统信号强度显著高于脑脊液,显著低于灰质和白质。
- 注射对比剂后,3D T1-SPACE序列中该系统信号强度先升高86.3±25.2%(TP2),随后下降25.4±9%(TP3)。
- 脑脊液、灰质和白质的信号强度在三个时间点间无显著变化。
临床应用与阅片要点
- 可采用2D T2-FLAIR与3D T1-SPACE序列观察类淋巴-淋巴流体运输系统。
- 注射钆对比剂后即刻与60分钟的信号强度变化可用于评估该系统动态变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Recently, a novel clearing system for interstitial solutes of the brain was described as a perivascular pathway named the glymphatic system. Furthermore, lymphatic vessels were found in the meninges to drain interstitial fluids. It is hypothesized that interstitial solutes, such as amyloid β, are firstly processed through the brain by the glymphatic system and secondly drained out of the brain by lymphatic vessels (glymphatic-lymphatic fluid transport system [GLS]). Since then, various neurological disorders, such as Alzheimer disease, have been associated with a dysfunction of the GLS. In the current study, we aimed to establish a clinical magnetic resonance imaging (MRI) study protocol for visualizing lymphatic vessels as part of the GLS in humans. More importantly, we aimed to describe the dynamic changes of a contrast agent in these lymphatic vessels over time.
MATERIALS AND METHODS: Twenty volunteers with an unremarkable neurological/psychiatric history were included in this 3T MRI study. Serial MRI sequence blocks were performed at 3 predefined time points (TPs): TP 1, precontrast MRI before administration of a gadolinium-based contrast agent (GBCA); TP 2, immediately post-GBCA (early ce-MRI); and TP 3, 60 minutes post-GBCA (late ce-MRI). Each MRI block contained the following sequences obtained in the same order: whole-brain 3D T1-MPRAGE, whole-brain 3D T2-FLAIR, focused 2D T2-FLAIR, and whole-brain 3D T1-SPACE. Signal intensity (SI) in compartments of the GLS adjacent to the superior sagittal sinus, gray matter (GM), white matter (WM), and cerebrospinal fluid (CSF) was calculated by manually placed regions of interest. The time course of the signal intensities was examined by generalized linear mixed models. The data were adjusted for age, cognitive function (Montreal-Cognitive-Assessment test), and sleep quality (Pittsburgh Sleep Quality Index questionnaire).
RESULTS: The GLS was best visualized in the 2D T2-FLAIR and 3D T1-SPACE sequences, enabling further SI measurement. In precontrast (TP 1), the SI within the GLS was significantly higher than in CSF and significantly lower than in GM and WM. In post-GBCA, a significant increase (TP 2) and decrease (TP 3), respectively, of the GLS SI values were noted (86.3 ± 25.2% increase and subsequent decrease by 25.4 ± 9% in the 3D T1-SPACE sequence). The SI values of CSF, GM, and WM did not change significantly between the 3 TPs.
CONCLUSIONS: A clinical MRI study protocol was established for the visualization of lymphatic vessels as an important part of the GLS and therefore the brain's clearing mechanism of interstitial solutes. Furthermore, dynamic changes in the GLS were described over time, possibly reflecting the clearing function of the GLS. This might constitute the basis for evaluating the GLS function in manifold neurological pathologies in the future.
引用
- Filippopulos, Fischer, Seelos, et al. Semiquantitative 3T Brain Magnetic Resonance Imaging for Dynamic Visualization of the Glymphatic-Lymphatic Fluid Transport System in Humans: A Pilot Study. Invest Radiol. 2022. PMID: 35763443. doi:10.1097/RLI.0000000000000870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。